Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

Mesotherapy with bicalutamide has limited effectiveness for female hair loss.

This review discusses treatments for female acne, highlighting the effectiveness of low-dose oral contraceptives and noting their similar side effects to placebo; it reports no new clinical results.

This study mapped potential targets and pathways for baicalin's action in androgenic alopecia, suggesting it may inhibit 5α-reductase and serve as an effective treatment ingredient.

This study observed some differences in clinical outcomes when comparing CPA with spironolactone, flutamide, and finasteride, but no differences with other therapies, possibly due to small study size and non-standardized assessments; adverse effects could not be fully compared across treatments.

Among cultured sebocytes, this study found that bilobetin significantly inhibited lipid production induced by IGF-1, suggesting potential for use in acne treatment.

Low-dose Ritlecitinib may help children with stubborn Alopecia Areata.

This review assessed the clinical and cost-effectiveness of baricitinib, an oral treatment for severe alopecia areata in adults, to inform Canadian reimbursement recommendations, excluding Quebec.

In this study, researchers found that ritlecitinib, a JAK3/TEC inhibitor, significantly improves hair regrowth, quality of life, and psychological well-being in patients with severe alopecia areata who had inadequate or no response to baricitinib, a JAK1/2 inhibitor.

This review discusses the pathophysiological characteristics and treatment options for polycystic ovary syndrome, reporting no new clinical results; the authors emphasize combining non-pharmacological measures with pharmacological treatments for optimal patient management.

This review discusses the use of ethinylestradiol combined with antiandrogenic progestin for treating androgenisation symptoms and improving metabolic and menstrual health in women, but it does not provide new clinical data.

Baricitinib is a safe and effective treatment for severe alopecia areata.

This review updates dermatologists on both FDA-approved and off-label hormonal therapies, including combined oral contraceptives, clascoterone, and spironolactone, used for acne treatment, providing insights into emerging approaches for managing the condition.

In this study, nearly one-third of patients with severe alopecia areata treated with ritlecitinib achieved complete scalp hair regrowth at least once over three years, and most maintained regrowth or stayed at low hair loss levels subsequently.

This 104-week follow-up trial found that baricitinib is effective and safe for treating severe alopecia areata but requires continuous use to sustain hair regrowth. The drug is included in the NVDV guidelines and reimbursed by Dutch insurers for this purpose.

This study found that bicalutamide mesotherapy resulted in subtle hair density improvements and was well tolerated by premenopausal women with androgenetic alopecia.

In this study, combining baricitinib and prednisone effectively achieved complete hair regrowth in seven out of eight women with very severe alopecia areata, contrasting with less effective results from each drug used alone.

This review discusses the therapeutic potential of costunolide for various diseases, highlighting its bioactivity and mechanisms, but it reports no new experimental results.

In this study, baricitinib was evaluated for its effectiveness in promoting concurrent regrowth of scalp hair, eyebrows, and eyelashes in patients with severe alopecia areata, showing clinically meaningful responses compared to placebo.

This study provides a narrative review suggesting GLP-1 receptor agonists could optimize metabolic health before conception in women with PCOS, but not necessarily improve fertility outcomes, emphasizing individualized use and the need for further research to confirm their reproductive benefits and safety.

This study found that treatment with cyproterone acetate was generally successful for women with virilizing features, showing improved results in younger women and those with adrenal hirsutism, despite some side effects.

This study found that oral contraceptives containing cyproterone acetate improved the overall quality of life in PCOS patients more than those containing levonorgestrel after 6 months of treatment.

This study found that oral baricitinib was more effective than methotrexate in treating severe alopecia areata, with significant improvements in SALT scores over six months.

This report highlights Amvuttra's approval for hATTR amyloidosis as a more convenient RNAi therapy, and Olumiant's attention as the first systemic drug for hair loss among recent developments.

This study found that while ethinyl oestradiol and cyproterone acetate effectively treated hirsutism in 90% of patients, 80% experienced relapse within six months after stopping treatment, suggesting long-term use is necessary.

This study used molecular docking to identify stiripentol as a potential new inhibitor of the SRD5A2 enzyme, which is targeted for treating androgen-related diseases; however, in vivo trials are needed to validate its efficacy.

In this study, single nucleotide polymorphisms in the RAB5B gene were linked to an increased risk of polycystic ovary syndrome and associated with specific microRNA binding sites.

This review discusses the use of different types of oral contraceptive pills and highlights their effectiveness, potential side effects, and contraindications without presenting new clinical data.

This study reports the discovery of LX-38, a novel non-steroidal drug candidate that may offer safer treatment for conditions like Benign Prostatic Hyperplasia by avoiding hormonal side effects associated with current therapies.